logo-loader

BioPorto submits kidney-injury test in children to FDA

Published: 13:56 03 Jun 2019 BST

BioPorto A/S (CPH:BIOPOR) CEO Peter Eriksen and US President Amy Winslow tell Proactive Investors the Danish company has submitted an application to FDA for approval of its proprietary NGAL Test that assesses the risk of acute kidney injury in children under 21.

Winslow adds color to the way in which the company will commercialize the diagnostic pending approval.

Ariana Resources updates resource and reserve; realises long-term strategy

Joining Jonathan Jackson in the Proactive studio is Ariana Resources PLC (AIM:AAU) managing director Kerim Sener, who sits down to discuss the latest resource and reserve update for the Zenit Mining Operations in Western Türkiye. The update encompasses the Kiziltepe and Tavsan sectors, operated...

7 hours, 3 minutes ago